Prosight Management, LP - Q2 2020 holdings

$233 Million is the total value of Prosight Management, LP's 52 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 77.3% .

 Value Shares↓ Weighting
NewISHARES TRput$27,920,000195,000
+100.0%
11.98%
ARNA SellARENA PHARMACEUTICALS INC$14,303,000
-18.8%
227,212
-45.9%
6.14%
-25.5%
RETA BuyREATA PHARMACEUTICALS INCcl a$12,809,000
+18.3%
82,100
+9.5%
5.50%
+8.6%
KURA SellKURA ONCOLOGY INC$11,166,000
-22.6%
685,000
-52.8%
4.79%
-28.9%
CNC BuyCENTENE CORP DEL$10,149,000
+20.0%
159,700
+12.2%
4.36%
+10.2%
ALXN SellALEXION PHARMACEUTICALS INC$10,102,000
-19.6%
90,000
-35.7%
4.34%
-26.2%
CHNG BuyCHANGE HEALTHCARE INC$9,297,000
+66.4%
830,100
+48.5%
3.99%
+52.9%
ZBH SellZIMMER BIOMET HOLDINGS INC$8,176,000
-23.0%
68,500
-34.8%
3.51%
-29.3%
ACIU BuyAC IMMUNE SA$7,920,000
+8.3%
1,176,801
+11.2%
3.40%
-0.6%
CUE SellCUE BIOPHARMA INC$7,605,000
-2.9%
310,294
-43.8%
3.26%
-10.9%
CI BuyCIGNA CORP NEW$7,225,000
+9.8%
38,500
+3.7%
3.10%
+0.8%
BMY NewBRISTOL-MYERS SQUIBB CO$6,938,000118,000
+100.0%
2.98%
ALDX SellALDEYRA THERAPEUTICS INC$6,756,000
+34.4%
1,620,200
-20.4%
2.90%
+23.4%
MGTX SellMEIRAGTX HLDGS PLC$6,510,000
-14.8%
519,967
-8.5%
2.79%
-21.8%
QURE SellUNIQURE NV$6,449,000
-44.7%
143,129
-41.7%
2.77%
-49.2%
IOVA SellIOVANCE BIOTHERAPEUTICS INC$5,902,000
-64.4%
215,000
-61.1%
2.53%
-67.3%
ALBO SellALBIREO PHARMA INC$5,266,000
-2.6%
198,800
-39.8%
2.26%
-10.6%
NewAPTOSE BIOSCIENCES INC$4,941,000783,073
+100.0%
2.12%
ARWR BuyARROWHEAD PHARMACEUTICALS IN$4,928,000
+63.6%
114,100
+8.9%
2.12%
+50.2%
CLLS NewCELLECTIS S Aspon ads$4,923,000276,577
+100.0%
2.11%
ZGNX SellZOGENIX INC$3,953,000
-2.3%
146,346
-10.6%
1.70%
-10.3%
ADMA BuyADMA BIOLOGICS INC$3,807,000
+6.4%
1,299,300
+4.6%
1.63%
-2.3%
BAX NewBAXTER INTL INC$3,659,00042,500
+100.0%
1.57%
NewBRISTOL-MYERS SQUIBB COcall$2,940,00050,000
+100.0%
1.26%
VCEL NewVERICEL CORP$2,901,000209,897
+100.0%
1.24%
PCRX NewPACIRA BIOSCIENCES$2,886,00055,000
+100.0%
1.24%
PSNL SellPERSONALIS INC$2,448,000
-26.9%
188,750
-54.5%
1.05%
-32.8%
ESTA BuyESTABLISHMENT LABS HLDGS INC$2,376,000
+29.8%
127,173
+0.4%
1.02%
+19.3%
IMVT SellIMMUNOVANT INC$2,325,000
+23.0%
95,500
-21.4%
1.00%
+13.0%
ORGO SellORGANOGENESIS HLDGS INC$2,057,000
-5.3%
535,616
-20.3%
0.88%
-13.0%
EHC SellENCOMPASS HEALTH CORP$2,037,000
-32.2%
32,900
-29.9%
0.87%
-37.7%
UTHR SellUNITED THERAPEUTICS CORP DEL$1,815,000
-79.6%
15,000
-84.0%
0.78%
-81.3%
TPTX NewTURNING POINT THERAPEUTICS I$1,654,00025,602
+100.0%
0.71%
TBIO NewTRANSLATE BIO INC$1,604,00089,510
+100.0%
0.69%
AUPH NewAURINIA PHARMACEUTICALS INC$1,495,00092,000
+100.0%
0.64%
EOLS SellEVOLUS INC$1,492,000
-30.1%
281,541
-45.2%
0.64%
-35.9%
CARA NewCARA THERAPEUTICS INC$1,487,00086,965
+100.0%
0.64%
CBIO SellCATALYST BIOSCIENCES INC$1,456,000
-13.0%
248,050
-35.2%
0.62%
-20.1%
MGTA NewMAGENTA THERAPEUTICS INC$1,266,000168,578
+100.0%
0.54%
AMN SellAMN HEALTHCARE SVCS INC$1,215,000
-74.8%
26,851
-67.8%
0.52%
-76.9%
NEO NewNEOGENOMICS INC$1,203,00038,819
+100.0%
0.52%
PRSC NewPROVIDENCE SVC CORP$1,178,00014,923
+100.0%
0.51%
EVFM NewEVOFEM BIOSCIENCES INC$1,168,000412,788
+100.0%
0.50%
BEAT NewBIOTELEMETRY INC$1,118,00024,733
+100.0%
0.48%
XERS NewXERIS PHARMACEUTICALS INC$1,116,000419,469
+100.0%
0.48%
LHCG SellLHC GROUP INC$786,000
-83.9%
4,509
-87.1%
0.34%
-85.3%
APEN BuyAPOLLO ENDOSURGERY INC$621,000
-4.2%
379,945
+12.7%
0.27%
-11.9%
MITO SellSTEALTH BIOTHERAPEUTICS CORPsponsored ads$533,000
+27.8%
291,144
-13.4%
0.23%
+17.4%
MGLN NewMAGELLAN HEALTH INC$379,0005,200
+100.0%
0.16%
New1LIFE HEALTHCARE INCput$291,0008,000
+100.0%
0.12%
NewZOGENIX INCput$221,0008,200
+100.0%
0.10%
SellEVOLUS INCcall$198,000
-35.3%
37,400
-49.3%
0.08%
-40.6%
MIST ExitMILESTONE PHARMACEUTICALS IN$0-41,592
-100.0%
-0.04%
THC ExitTENET HEALTHCARE CORP$0-20,918
-100.0%
-0.14%
KZR ExitKEZAR LIFE SCIENCES INC$0-96,615
-100.0%
-0.20%
NSP ExitINSPERITY INC$0-12,900
-100.0%
-0.22%
HCA ExitHCA HEALTHCARE INC$0-9,223
-100.0%
-0.39%
LGND ExitLIGAND PHARMACEUTICALS INC$0-11,500
-100.0%
-0.39%
NVST ExitENVISTA HOLDINGS CORPORATION$0-58,000
-100.0%
-0.40%
ExitCHANGE HEALTHCARE INCcall$0-100,000
-100.0%
-0.47%
ANAB ExitANAPTYSBIO INC$0-78,976
-100.0%
-0.52%
ABBV ExitABBVIE INC$0-16,030
-100.0%
-0.57%
BMRN ExitBIOMARIN PHARMACEUTICAL INC$0-22,900
-100.0%
-0.90%
URGN ExitUROGEN PHARMA LTD$0-146,179
-100.0%
-1.22%
TZA ExitDIREXION SHS ETF TRdaily sm cp bear$0-125,000
-100.0%
-3.47%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2020-08-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ALDEYRA THERAPEUTICS INC19Q2 20236.2%
ALBIREO PHARMA INC18Q4 20229.2%
MEIRAGTX HOLDINGS PLC18Q3 20236.3%
KEZAR LIFE SCIENCES INC17Q3 20238.2%
ARENA PHARMACEUTICALS INC16Q4 20218.2%
IOVANCE BIOTHERAPEUTICS INC16Q1 20227.7%
CENTENE CORP DEL16Q3 20235.3%
CUE BIOPHARMA INC14Q1 20235.6%
PROTHENA CORP PLC13Q3 202313.6%
ZIMMER BIOMET HOLDINGS INC13Q3 20219.8%

View Prosight Management, LP's complete holdings history.

Latest significant ownerships (13-D/G)
Prosight Management, LP Q2 2020 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
EXICURE, INC.February 14, 20222,426,5082.2%
Aldeyra Therapeutics, Inc.February 12, 2021908,4882.3%
Teligent, Inc.February 14, 20201,484,5272.8%
Cidara Therapeutics, Inc.February 14, 2019245,7640.9%
Eiger BioPharmaceuticals, Inc.Sold outFebruary 14, 201900.0%
Millendo Therapeutics, Inc.February 14, 2019256,7392.0%
OvaScience, Inc.October 26, 20181,991,1005.6%
CHIMERIX INCFebruary 13, 20181,478,5193.1%
Harvard Apparatus Regenerative Technology, Inc.February 12, 2016184,3601.4%

View Prosight Management, LP's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-02-14
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G2024-01-02
13F-HR2023-11-14
SC 13G2023-09-01

View Prosight Management, LP's complete filings history.

Compare quarters

Export Prosight Management, LP's holdings